An interventional study of VOCALE LBD: Virtual Online Communities for Aging Life Experiences: Lewy Body Dementia and Standard of Care Educational Materials in Lewy Bodies Disease, Depression Disorder and Caregiver Burden, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Washington · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies in Caregiver Burden with a site in United States — 59 open to participants now, 71 under way, 1 of them phase 3. Caregiver Burden · United States.
Among the 228 studies in Caregiver Burden with a site in United States, this one is the 36th largest by planned enrollment of the 208 interventional ones that give a count, is one of 19 that started in 2026, is one of 190 with no phase, reaches primary completion later than 64 of the 70 other live ones, and was the 216th registered.
503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.
Browse Caregiver Burden studies →59 of the 228 studies in Caregiver Burden with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Caregiver Burden studies recruiting now, 69 (77%) set no upper age limit and 7 (8%) stop at 75 or younger; 8 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4 · Phase 4 2
First in 2000; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 73 across 404 interventional studies indexed under Caregiver Burden.
Median enrollment 60 across the 208 interventional studies, 47 across the 19 observational. Of the 140 that completed or were terminated, 54 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 228 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
University of Washington has 5 studies filed under Caregiver Burden — fewer than ten, so there is no comparison to draw.
29 of the studies in Caregiver Burden with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06167746Phase 3University of PennsylvaniaiCare4Me Transitions | 2027-09-30 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT06099197Indiana UniversityI-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals | 2026-11 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
| NCT06460012Oregon Health and Science UniversitySupport Via Technology: Living and Learning With Advancing Dementia-REVISED | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 228 studies in Caregiver Burden with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether a tailored, fully asynchronous online group intervention (VOCALE LBD) reduces depression in family caregivers of people with Lewy Body Dementia (LBD), compared to standard educational materials. LBD is the second most common form of degenerative dementia and causes distinct challenges, including visual hallucinations, REM sleep disorder, and severe motor symptoms, that are not addressed by generic caregiver interventions. Depression rates in LBD caregivers reach 40-50%, double the rate seen in Alzheimer's disease caregivers, yet no rigorous digital interventions exist specifically for this population. VOCALE LBD is a text-based, low-bandwidth platform (Discourse) that brings groups of 10-15 caregivers together in an 8-week moderated online community. Weekly topics address LBD-specific challenges (sleep problems, hallucinations, self-care) and problem-solving skills using the ADAPT method. A pilot study (n=54) showed strong effects on depressive symptoms (Cohen's d=0.54 at 1-month follow-up), near-perfect engagement, and high participant satisfaction. This RCT (N=220) will test efficacy, examine mechanisms of action (self-efficacy and problem-solving), and explore analytics approaches for pragmatic monitoring, laying groundwork for future implementation in clinics and community organizations.
Over 1.4 million people in the U.S. are diagnosed with Lewy Body Dementia (LBD). Up to 80% receive care from family members, yet family caregivers of people with LBD experience depression at rates (40-50%) double those of Alzheimer's disease caregivers. LBD's distinct features - visual hallucinations, REM sleep behavior disorder, cognitive fluctuations, and Parkinsonian motor symptoms - create caregiving demands not addressed by existing dementia caregiver interventions. Current pharmacological treatments for LBD are largely experimental, leaving families to manage severe behavioral and motor symptoms without adequate support. INTERVENTION: VOCALE LBD (Virtual Online Communities for Aging Life Experiences - Lewy Body Dementia) is a fully asynchronous, text-based online group intervention delivered via the Discourse platform. The 8-week program includes icebreaker activities followed by LBD-specific weekly topics (self-care, sleep problems, hallucinations and delusions) and problem-solving training using the ADAPT method (Adopting a positive attitude, Defining the problem, brainstorming Alternatives, Predicting consequences, Trying the solution). Groups of 10-15 caregivers are moderated by a licensed nurse or social worker (RN/LCSW), who logs in daily and facilitates discussions. The platform requires no video conferencing and is accessible via any internet-connected device. Loaner devices and digital literacy training are provided for participants who need them. STUDY DESIGN: Two-arm, randomized controlled trial. Participants are randomized 1:1 to (a) VOCALE LBD or (b) Standard of Care (SOC: NIA psychoeducational materials, LBDA resource list, problem-solving handouts). Assessment time points: baseline, post-intervention (week 8), and 6-month follow-up. Exit interviews are conducted at the end of the intervention. AIMS: Aim 1 tests whether VOCALE LBD reduces depressive symptoms (CES-D) compared to SOC at week 8, with sustained effect at 6 months. Aim 2 examines mechanisms - whether self-efficacy and problem-solving mediate outcomes (2a quantitative mediation; 2b qualitative analysis). Aim 3 explores pragmatic monitoring using user engagement analytics, natural language processing, and LLM-assisted moderator support tools. RECRUITMENT: Nationwide recruitment through the Lewy Body Dementia Association (LBDA) via eblasts, social media, support groups, and print materials. Additional outreach via Alzheimer.gov and national LBD caregiver web resources.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm receive the VOCALE LBD intervention: an 8-week, fully asynchronous, text-based online group program delivered via the Discourse platform. Groups of 10-15 participants are facilitated by trained moderators who log in daily. Weekly discussion topics address LBD-specific caregiving challenges (sleep problems, hallucinations and delusions) and problem-solving skills training using the ADAPT method. Participants are asked to make a minimum of three posts each week (e.g., adding a post, replying to two other users).
Behavioral: VOCALE LBD: Virtual Online Communities for Aging Life Experiences: Lewy Body Dementia
NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email.
Other: Standard of Care Educational Materials
The 8-week VOCALE LBD intervention is delivered asynchronously via the Discourse online platform. The weekly curriculum includes: Pre-intervention (Icebreakers, Self-introductions); Week 1 (Sleep Problems); Week 2 (Hallucinations and Delusions); Week 3 (ADAPT - Positive Attitude); Week 4 (ADAPT - Define the Problem); Week 5 (ADAPT - Alternative Solutions); Week 6 (ADAPT - Plan); Week 7 (ADAPT - Try); Week 8 (Reflection and Wrap Up).
Also known as: VOCALE LBD, Virtual Online Community, Asynchronous Online Group Intervention
NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email or mail per participant preference.
Center for Epidemiologic Studies Depression Scale (CES-D)
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report questionnaire that evaluates the frequency of depressive symptoms experienced in the past week (including depressed mood, feelings of guilt/worthlessness, helplessness, and physical symptoms). Total scores range from 0 to 60. Higher scores indicate greater severity of depressive symptoms (worse outcome).
Time frame: Baseline (pre-randomization), Post-intervention (Week 8), 6-month follow-up
Short Zarit Caregiver Burden Interview (ZBI-12)
The Short Zarit Caregiver Burden Interview (ZBI-12) is a 12-item self-report instrument that measures personal strain and role strain associated with caregiving. Total scores range from 0 to 48. Higher scores indicate greater caregiver burden (worse outcome).
Time frame: Baseline, Week 8, 6-month follow-up
UCLA Loneliness Scale (3-Item Short Form)
The UCLA Loneliness Scale (3-Item Short Form) is a 3-item self-report survey assessing subjective feelings of loneliness and social isolation. Total scores range from 3 to 9. Higher scores indicate greater loneliness and social isolation (worse outcome).
Time frame: Baseline, Week 8, 6-month follow-up
Perceived Stress Scale (PSS-10)
The Perceived Stress Scale (PSS-10) is a 10-item instrument measuring an individual's perception of stress and feelings of unpredictability, uncontrollability, and overload during the past month. Total scores range from 0 to 40. Higher scores indicate greater perceived stress (worse outcome).
Time frame: Baseline, Week 8, 6-month follow-up
Medical Outcomes Study Social Support Survey (MOS-SSS)
The Medical Outcomes Study Social Support Survey (MOS-SSS) is a 19-item questionnaire evaluating multiple dimensions of social support (emotional/informational, tangible, affectionate, and positive social interaction). Raw total scores range from 19 to 95 (which can be transformed to an overall index score of 0 to 100). Higher scores indicate greater social support (better outcome).
Time frame: Baseline, Week 5 (mid-intervention), Week 8, 6-month follow-up
Social Problem-Solving Inventory-Revised (SPSI-R Short Form)
The Social Problem-Solving Inventory-Revised (SPSI-R:S) is a 25-item self-report instrument assessing cognitive and behavioral problem-solving orientations and skills across five subscales (Positive Problem Orientation, Negative Problem Orientation, Rational Problem Solving, Impulsivity/Carelessness Style, and Avoidance Style). Standardized total scores range from 0 to 20. Higher total scores indicate better social problem-solving skills (better outcome). Used as mechanistic measure.
Time frame: Baseline, Week 5, Week 8, 6-month follow-up
General Self-Efficacy Scale (GSE)
The General Self-Efficacy Scale (GSE) is a 10-item self-report questionnaire assessing optimistic self-beliefs and confidence in coping with daily difficulties and novel situations. Total scores range from 10 to 40. Higher scores indicate greater general self-efficacy (better outcome).
Time frame: Baseline, Week 5, Week 8, 6-month follow-up
Caregiver Self-Efficacy Scale (CSES-8)
The Caregiver Self-Efficacy Scale is an 8-item self-report questionnaire measuring caregiver confidence in managing caregiving demands, obtaining respite, and handling challenging behaviors. Total scores range from 0 to 100 (percent confidence). Higher scores indicate greater caregiver self-efficacy (better outcome).
Time frame: Baseline, Week 5, Week 8, 6-month follow-up
User Engagement Scale (UES)
The User Engagement Scale (UES) is a 31-item self-report survey characterizing the depth and quality of participant interactions with the online discussion platform across four subdomains (focused attention, perceived usability, aesthetic appeal, and reward). Mean item scores range from 1 to 5. Higher scores indicate greater platform engagement (better outcome).
Time frame: Week 8
Benefits of Participating Scale
The Benefits of Participating Scale is a 4-item questionnaire evaluating perceived personal benefit and satisfaction with program participation (rated on a 3-point scale: 1 = Not at all, 2 = Some, 3 = A great deal). Total scores range from 4 to 12. Higher scores indicate greater perceived benefit and study satisfaction (better outcome).
Time frame: Week 8, 6-month follow-up
Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications (text, tables, figures, appendices) will be shared. Data will be made available 9 months following publication of the primary study results. Data will be deposited in an NIH-designated repository (e.g., NIMH Data Archive or ICPSR). Requests for data should include a data analysis plan and be submitted to the PI.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 9 months after publication of primary outcome results; available for 5 years.
Access criteria: Researchers who provide a methodologically sound data analysis plan. Proposals should be directed to zaslav@uw.edu. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.
Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 35 months is above that.
Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.